CA77.1 Clinical Trials

Size	Price	Qty
5mg	USD 227
25mg	USD 687

Clinical Trials

Several clinical trials investigate diverse conditions ranging from oncology to psychiatric disorders, including Lynch syndrome, recurrent uterine corpus carcinoma, surgical recovery in colorectal disorders, and adolescent post-traumatic stress disorder. Spanning Phase 2 evaluations, non-applicable phase designations, and unassigned phase protocols, these studies are all currently categorized as not yet recruiting. Sponsoring institutions include the National Cancer Institute, the GOG Foundation, the University of Alabama at Birmingham, and the University of California, Los Angeles.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01199250	Not yet recruiting	Lynch Syndrome\|Recurrent Uterine Corpus Carcinoma\|Stage I Uterine Corpus Cancer\|Stage II Uterine Corpus Cancer\|Stage III Uterine Corpus Cancer\|Stage IV Uterine Corpus Cancer	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	2100-01	--
NCT01164735	Not yet recruiting	Recurrent Uterine Corpus Carcinoma\|Stage III Uterine Corpus Cancer\|Stage IV Uterine Corpus Cancer	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	2100-01	--
NCT06356558	Not yet recruiting	Surgery\|Health Knowledge Attitudes Practice\|Colorectal Disorders	University of Alabama at Birmingham\|National Cancer Institute (NCI)	2026-05	Not Applicable
NCT06353282	Not yet recruiting	PTSD Post Traumatic Stress Disorder\|Adolescents\|Psychotherapy	University of California Los Angeles	2025-07-01	Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the CA77.1 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

CA77.1 functions as a brain-penetrant activator of chaperone-mediated autophagy, directly stimulating the selective lysosomal translocation and enzymatic degradation of target intracellular proteins. By accelerating autophagic clearance and maintaining proteostasis, this compound reduces cellular cytotoxicity, supporting its therapeutic potential in neurodegenerative pathology such as Alzheimer's disease and related clinical trial targets including uterine corpus carcinoma and Lynch syndrome.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).